Viva Biotech Holdings (VB0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Viva Biotech Holdings (VB0) has a cash flow conversion efficiency ratio of 0.044x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€158.72 Million ≈ $185.57 Million USD) by net assets (€3.64 Billion ≈ $4.26 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Viva Biotech Holdings (VB0) balance sheet quality index to measure how much of total assets are equity-financed.
Viva Biotech Holdings - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Viva Biotech Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Viva Biotech Holdings cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Viva Biotech Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viva Biotech Holdings ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tien Phong Securities Corp
VN:ORS
|
-0.314x |
|
Aramis SAS
PA:ARAMI
|
0.246x |
|
Ratos AB (publ)
ST:RATO-A
|
0.001x |
|
Monarch Networth Capital Limited
NSE:MONARCH
|
0.001x |
|
Xinjiang Talimu Agriculture Development Co Ltd
SHG:600359
|
-0.010x |
|
Transcontinental Realty Investors
NYSE:TCI
|
-0.003x |
|
Kits Eyecare Ltd
TO:KITS
|
-0.071x |
|
Nanjing Res In of Surveying Mapping
SHE:300826
|
0.002x |
Annual Cash Flow Conversion Efficiency for Viva Biotech Holdings (2016–2024)
The table below shows the annual cash flow conversion efficiency of Viva Biotech Holdings from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Viva Biotech Holdings market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €3.82 Billion ≈ $4.46 Billion |
€373.99 Million ≈ $437.23 Million |
0.098x | -5.74% |
| 2023-12-31 | €3.69 Billion ≈ $4.31 Billion |
€383.40 Million ≈ $448.24 Million |
0.104x | -2.93% |
| 2022-12-31 | €3.60 Billion ≈ $4.21 Billion |
€386.05 Million ≈ $451.33 Million |
0.107x | +438.49% |
| 2021-12-31 | €3.91 Billion ≈ $4.58 Billion |
€77.83 Million ≈ $90.99 Million |
0.020x | +73.03% |
| 2020-12-31 | €3.76 Billion ≈ $4.39 Billion |
€43.18 Million ≈ $50.48 Million |
0.011x | -55.60% |
| 2019-12-31 | €1.78 Billion ≈ $2.08 Billion |
€46.01 Million ≈ $53.79 Million |
0.026x | -46.25% |
| 2018-12-31 | €251.44 Million ≈ $293.96 Million |
€12.11 Million ≈ $14.16 Million |
0.048x | -73.62% |
| 2017-12-31 | €152.76 Million ≈ $178.59 Million |
€27.89 Million ≈ $32.61 Million |
0.183x | -33.86% |
| 2016-12-31 | €76.50 Million ≈ $89.44 Million |
€21.12 Million ≈ $24.69 Million |
0.276x | -- |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more